Sanofi, Sema4, Mount Sinai Collaborate on Largest Asthma Study of Its Kind
Five-year multiscale study will follow 1,200 patients using advanced network modeling to make new discoveries
Sema4, a patient-centered predictive health company, and the Mount Sinai Health System today announced the launch of a five-year collaborative study with Sanofi designed to provide new insights into the biological mechanisms and other factors implicated in asthma. The project will follow nearly 1,200 people with asthma and collect a range of data — from traditional clinical data to genomics, immunological, environmental, and sensor data from mobile devices — to enable sophisticated analysis and advanced network modeling of this complex disease.
Asthma is the most prevalent chronic respiratory disease, affecting more than 350 million people worldwide and causing approximately 400,000 deaths worldwide annually1. Evidence shows that the prevalence of asthma is increasing, and along with it both direct healthcare costs as well as indirect costs from loss of productivity and early disability.
“Despite advances in recent years, we still see many patients struggling with asthma, so there is still a tremendous need for innovation to reduce the burden of this disease,” said Linda Rogers, MD, Associate Professor and Clinical Director of the Adult Asthma Program at the Mount Sinai - National Jewish Health Respiratory Institute. “With one of the largest asthma programs in the region, caring for patients across the spectrum of severity of asthma, the Mount Sinai - National Jewish Health Respiratory Institute will play a crucial role in this partnership to advance our understanding of asthma and develop personalized therapies for our patients.”
The study will generate real-world data about patients through innovative molecular profiling of biological samples and digital monitoring of the environment. Clinical research teams from all three organizations will deploy advanced analytics on this information to better understand how the disease functions, what triggers asthma attacks, which patient segments are most likely to respond to certain therapies, why the disease affects people differently, and more. Researchers hope these insights will help pinpoint new therapeutic targets as well as more effective treatment recommendations for patients.
“Understanding how to develop new treatments for asthma starts with a better understanding of the disease,” said Frank Nestle, Global Head of Immunology and Inflammation Research and Chief Scientific Officer, North America, at Sanofi. “Our goal is to develop a holistic view of each patient in the study, which is why we’re excited to add digital technology to the traditional types of medical examinations conducted in this study. It’s a new way to approach this enormous problem, connecting real world clinical and scientific data, that we hope will translate into new ways to treat asthma.”
“Asthma is an incredibly complex condition associated with genetics, environmental factors, activity levels, the immune system and more,” said Eric Schadt, PhD, Chief Executive Officer of Sema4. “We believe the only way to fully understand asthma is by using sophisticated modeling tools to mine the rich, multi-dimensional data set we aim to generate in this study. This approach could reveal entirely new avenues for alleviating and more effectively treating asthma.”
“Mount Sinai has incredible clinicians who care for a diverse patient population and is backed by world-class data science and multiscale biological modeling capabilities,” said Andrew Kasarskis, PhD, Vice Chair, Department of Genetics and Genomic Sciences. “In this groundbreaking collaboration with Sanofi and Sema4, we are thrilled to leverage the Mount Sinai ecosystem and build on our experience with another immune condition, inflammatory bowel disease. Together, we will define asthma subtypes clinically, then understand the molecular basis of disease in each subtype in order to discover new therapies and better manage asthma in all our patients.”
“We’re pleased to partner with Sanofi and Sema4 on this exciting new study,” said Erik Lium, PhD, Executive Vice President of Mount Sinai Innovation Partners. “We believe this collaboration may ultimately lead to the identification of novel targets and the development of groundbreaking therapies to benefit patients with asthma.”
1. GBD 2015 Chronic Respiratory Disease Collaborators. “Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015.” Lancet Respir Med 2017; 5: 691–706. http://dx.doi.org/10.1016/S2213-2600(17)30293-X.
Sema4 is a patient-centered predictive health company founded on the idea that more information, deeper analysis, and increased engagement will improve the diagnosis, treatment, and prevention of disease. A Mount Sinai Health System venture based in Stamford, Connecticut, Sema4 is dedicated to transforming healthcare by building more dynamic models of human health and defining optimal, individualized health trajectories, starting with reproductive health and oncology. Our innovative Sema4 Health Intelligence Platform is enabling us to generate a more complete understanding of disease and wellness and to provide science-driven solutions to the most pressing medical needs. Sema4 believes that patients should be treated as partners, and that data should be shared for the benefit of all.
About the Mount Sinai Health System
The Mount Sinai Health System is New York City's largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai is a national and international source of unrivaled education, translational research and discovery, and collaborative clinical leadership ensuring that we deliver the highest quality care—from prevention to treatment of the most serious and complex human diseases. The Health System includes more than 7,200 physicians and features a robust and continually expanding network of multispecialty services, including more than 400 ambulatory practice locations throughout the five boroughs of New York City, Westchester, and Long Island. The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report's "Honor Roll" of the Top 20 Best Hospitals in the country and the Icahn School of Medicine as one of the Top 20 Best Medical Schools in country. Mount Sinai Health System hospitals are consistently ranked regionally by specialty and our physicians in the top 1% of all physicians nationally by U.S. News & World Report.